Utah Medical Products, Inc. (UTMD)

In the past six months, Utah Medical Products, Inc. was downgraded to 'hold' due to declines in revenue, profits, and cash flow, primarily attributed to reduced sales to PendoTECH and margin pressures from an unfavorable product mix in Ireland. For the full calendar year 2025, UTMD reported consolidated revenues of $38.5 million, a 5.8% decrease from 2024, with net income declining by 19% and EPS by 12%. The company increased its year-end cash to $85.8 million after share repurchases and dividends. The stock's 12-month price change was approximately +13.5%, recovering from a prior-year trough due to investors taking comfort in the company's strong cash and investment balances. As of March 19, 2026, the share price was $64.00, an increase of 11.48% from March 20, 2025.

Information regarding the seasonality of demand for Utah Medical Products, Inc.'s specific products and services is not explicitly detailed. Analysis of UTMD's historical stock price data suggests some seasonality in stock returns, with November historically showing the highest probability of positive returns and February the lowest. The company's business model is built around stable, high-margin consumable sales, with occasional spikes or drops depending on partner relationships and international shipment timing. International shipment timing, distributor cancellations, and tariff changes can create quarter-to-quarter volatility in sales.

Utah Medical Products, Inc. (UTMD) is a specialized medical device company focused on niche markets like women's health, neonatal intensive care, and critical care. The company develops and commercializes medical technologies that offer clinical advantages and economic benefits, delivering high-quality solutions to a global customer base. UTMD's major product categories include neonatal care, surgical products, urological devices, labor and delivery/obstetrics, blood pressure monitoring and blood management, gynecology/women's pelvic health, electrosurgery, and OEM/capabilities.

Utah Medical Products, Inc. serves hospitals, clinics, and distributors across North America, Europe, Asia, and other international markets. The company's headquarters are in Midvale, Utah, and it operates four facilities outside the United States: in Romsey, England; Castle Hill, Australia; Mississauga, Canada; and Athlone, Ireland. UTMD relies on third-party distributors in some regions and faces risks related to regulatory and geopolitical environments, particularly in countries like China, Pakistan, and India.

Utah Medical Products, Inc. has generally built a reputation for exceptional product reliability and clinical performance. However, in the past year, the company's reputation has been significantly impacted by serious lawsuits related to its Filshie Clip System, leading to substantial legal costs. The company expects these lawsuits not to materially impact its overall finances, but the cost of defending them is significant and an ongoing concern. The decline in sales of the Filshie device has also been noted as a factor in the company's revenue decrease.

Utah Medical Products, Inc. has 159 institutional owners and shareholders holding a total of 2,208,602 shares. Institutional ownership accounts for approximately 59.73% to 65.89% of the company, while individual ownership is around 7.14%, and insider ownership is 3.15%. Major institutional owners include Brandes Investment Partners, Lp, Dimensional Fund Advisors Lp, Renaissance Technologies Llc, BlackRock, Inc., and Vanguard Group Inc.